CurrentCardio
Get Weekly

Topic

Cardiometabolic & kidney

Diabetes, obesity, CKD and their cardiovascular or cardiorenal outcomes, SGLT2i/GLP-1 RA outside a primary HF population

235 Briefs placed here197 mores indexed under this topic as a secondary topic

Briefs in Cardiometabolic & kidney

Newest publication first

  1. Eur J Heart Fail

    Clinical trajectory and disease progression in patients with cardio-renal-metabolic syndrome: the CaReMap observational study

    Cohort study

  2. JACC Adv

    Projected Impact of LDL-C and HbA1c Control on Cardiovascular Outcomes in ASCVD and Diabetes

    Cross-sectional study

  3. Am Heart J

    Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

    Trial design

  4. Lancet

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

    Randomised controlled trial

  5. Eur J Heart Fail

    Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis

    Secondary analysis

  6. Eur J Prev Cardiol

    Alcohol use disorder and cardiovascular risk in type 2 diabetes: beyond alcohol consumption

    Cohort study

  7. Circulation

    Women’s Kidney Health in Focus: A Scientific Statement From the American Heart Association

    Guideline or statement

  8. Eur J Prev Cardiol

    Low-grade inflammation predicts major cardiovascular events and mortality in recently diagnosed type 2 diabetes: a Danish nationwide cohort study

    Cohort study

  9. BMJ

    Simultaneous derivation, validation, and comparison of predictor hazard ratios for cardiovascular risk prediction equations in patients with diabetes from high versus non-high income countries: cohort study

    Cohort study

  10. Eur Heart J Cardiovasc Pharmacother

    Vagal activity-related events and glucagon-like peptide-1 receptor agonists

    Research article

  11. Eur Heart J

    Subclinical liver disease and incident cardiovascular events

    Cohort study

  12. JACC Adv

    Cardiometabolic and ASCVD Risk Profiles in Arab Americans

    Cohort study

  13. JACC Heart Fail

    Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes

    Secondary analysis

  14. Eur Heart J

    Mapping organ fat distribution and body composition: towards precision profiling of cardiometabolic disease risk

    Cohort study

  15. Eur Heart J

    Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis

    Secondary analysis

  16. Eur Heart J

    Clonal haematopoiesis and cardiovascular-kidney-metabolic syndrome: a cohort study

    Cohort study

  17. Eur Heart J

    Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk

    Diagnostic or prognostic study

  18. Circulation

    Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes

    Mechanistic study

  19. JACC Adv

    Life's Essential 8 Score and Cardiovascular-Kidney Outcomes in ASCVD: A UK Biobank Prospective Cohort Study

    Cohort study

  20. Circ Popul Health Outcomes

    Association Between Cardiovascular-Kidney-Metabolic Health and Early Arterial Injury in Young Adults in the United States: The Future of Families–Cardiovascular Health Among Young Adults Study

    Cross-sectional study

  21. Circulation

    Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

    Secondary analysis

  22. Am Heart J

    Cleaner air for lower cardiometabolic risk: Protocol for a double-blind, randomized, sham-controlled trial of HEPA filtration in adults with prediabetes

    Trial design

  23. Circ Heart Fail

    Elevated Endogenous Insulin and Insulin Resistance Are Associated With Progressive Diastolic Dysfunction and Worse Cardiovascular Outcomes

    Cohort study

  24. JACC Adv

    Diabetes Mellitus, Cumulative Glucose Exposure, and Incident Cardiovascular Disease Risk

    Research article

  25. BMJ

    Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study

    Cohort study

  26. Eur J Prev Cardiol

    Cardiovascular–kidney–metabolic syndrome and long-term risk of cardiovascular disease and all-cause mortality

    Cohort study

  27. JAMA

    Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

    Randomised controlled trial

  28. Am Heart J

    Rationale, design, and experiences from the vanguard phase of the bariatric surgery for the reduction of cardiovascular events (BRAVE) trial

    Trial design

  29. Circulation

    Effects of a “Food Is Medicine” Intervention on Glucose Control Among Medicaid-Insured Patients With Type 2 Diabetes: A Randomized Controlled Trial

    Randomised controlled trial

  30. JACC CardioOncol

    Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk

    Cohort study

  31. Eur J Prev Cardiol

    Long-term major adverse cardiovascular and cerebrovascular event risk in adult-onset type 1 versus type 2 diabetes: a propensity-matched cohort study

    Cohort study

  32. Lancet

    Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies

    Meta-analysis

  33. JAMA Cardiol

    Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages

    Meta-analysis

  34. JAMA Cardiol

    Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring

    Cohort study

  35. Heart

    Heart failure and renal outcomes with angiotensin receptor blockers compared with calcium channel blockers in patients with chronic kidney disease: a target trial emulation

    Research article

  36. Eur Heart J Cardiovasc Pharmacother

    Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation

    Cohort study

  37. Circ Popul Health Outcomes

    Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance

    Cohort study

  38. Heart

    Sex-specific associations between midlife body mass index and later-life left atrial enlargement in the Hordaland health study

    Research article

  39. J Am Coll Cardiol

    2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

    Guideline or statement

  40. Circulation

    2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

    Guideline or statement

All 235 Briefs in ExploreShowing the 40 most recently published